Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04044859
Title	ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Adaptimmune
Indications	esophageal cancer gastroesophageal junction adenocarcinoma transitional cell carcinoma head and neck cancer ovarian cancer stomach cancer melanoma endometrial cancer lung non-small cell carcinoma
Therapies	ADP-A2M4 cells ADP-A2M4 cells + Pembrolizumab ADP-A2M4 cells + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| CAN \| BEL